{"id":"https://openalex.org/W2965664826","doi":"https://doi.org/10.1182/blood.v130.suppl_1.819.819","title":"In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma","display_name":"In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W2965664826","doi":"https://doi.org/10.1182/blood.v130.suppl_1.819.819","mag":"2965664826"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v130.suppl_1.819.819","doi":"https://doi.org/10.1182/blood.v130.suppl_1.819.819","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v130.suppl_1.819.819","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062879857","display_name":"Alison J. Moskowitz","orcid":"https://orcid.org/0000-0002-3408-050X","observed_orcids":["https://orcid.org/0000-0002-3408-050X"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alison J. Moskowitz","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046212667","display_name":"Raphael Koch","orcid":"https://orcid.org/0000-0002-2018-5685","observed_orcids":["https://orcid.org/0000-0002-2018-5685"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raphael Koch","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063072439","display_name":"Neha Mehta\u2013Shah","orcid":"https://orcid.org/0000-0001-5744-0670","observed_orcids":["https://orcid.org/0000-0001-5744-0670"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neha Mehta-Shah","raw_affiliation_strings":["Department of Medicine, Division of Oncology, Washington University School of Medicine, Olivette, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Oncology, Washington University School of Medicine, Olivette, MO","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083629751","display_name":"Patricia L. Myskowski","orcid":"https://orcid.org/0000-0001-6903-3335","observed_orcids":["https://orcid.org/0000-0001-6903-3335"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Patricia Myskowski","raw_affiliation_strings":["Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028335400","display_name":"Meenal Kheterpal","orcid":"https://orcid.org/0000-0002-0460-6400","observed_orcids":["https://orcid.org/0000-0002-0460-6400"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Meenal Kheterpal","raw_affiliation_strings":["Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024505450","display_name":"Ahmet Do\u01e7an","orcid":"https://orcid.org/0000-0001-6576-5256","observed_orcids":["https://orcid.org/0000-0001-6576-5256","https://orcid.org/0000-0003-1818-9764"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmet Dogan","raw_affiliation_strings":["Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054774404","display_name":"Theresa Davey","orcid":"https://orcid.org/0000-0002-4262-1054","observed_orcids":["https://orcid.org/0000-0002-4262-1054"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Theresa Davey","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066589631","display_name":"Natasha Galasso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Natasha Galasso","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046862995","display_name":"Evan Marzouk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Marzouk Evan","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Monica Shah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Monica Shah","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103005320","display_name":"Nivetha Ganesan","orcid":"https://orcid.org/0009-0005-3491-8033","observed_orcids":["https://orcid.org/0009-0005-3491-8033"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nivetha Ganesan","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046832037","display_name":"Lakeisha Lubin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lakeisha Lubin","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103275168","display_name":"Youn H. Kim","orcid":"https://orcid.org/0000-0003-2686-5873","observed_orcids":["https://orcid.org/0000-0003-2686-5873"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Youn H. Kim","raw_affiliation_strings":["Stanford University, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Stanford, CA","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057879662","display_name":"Michael Siavash Khodadoust","orcid":"https://orcid.org/0000-0001-9061-7351","observed_orcids":["https://orcid.org/0000-0001-9061-7351"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Khodadoust","raw_affiliation_strings":["Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Stanford, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076808556","display_name":"Timothy Hermosura Almazan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Timothy Almazan","raw_affiliation_strings":["Stanford University Medical Center, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University Medical Center, Palo Alto, CA","institution_ids":["https://openalex.org/I4210137306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049108815","display_name":"Julia Dai","orcid":"https://orcid.org/0000-0002-3061-6231","observed_orcids":["https://orcid.org/0000-0002-3061-6231"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Julia Dai","raw_affiliation_strings":["Stanford University Medical Center, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University Medical Center, Palo Alto, CA","institution_ids":["https://openalex.org/I4210137306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083104525","display_name":"Eric D. Jacobsen","orcid":"https://orcid.org/0000-0003-3014-0023","observed_orcids":["https://orcid.org/0000-0003-3014-0023"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric D. Jacobsen","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026688095","display_name":"David M. Weinstock","orcid":"https://orcid.org/0000-0002-8724-3907","observed_orcids":["https://orcid.org/0000-0002-8724-3907"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Weinstock","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069406522","display_name":"Steven Michael Horwitz","orcid":"https://orcid.org/0000-0002-6399-2006","observed_orcids":["https://orcid.org/0000-0002-6399-2006"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Horwitz","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5028335400","https://openalex.org/A5046862995","https://openalex.org/A5049108815","https://openalex.org/A5066589631","https://openalex.org/A5076808556","https://openalex.org/A5083104525","https://openalex.org/A5083629751"],"corresponding_institution_ids":["https://openalex.org/I1334819555","https://openalex.org/I4210117453","https://openalex.org/I4210137306"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"130","issue":"Suppl_1","first_page":"819","last_page":"819"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9437999725341797,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9437999725341797,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.014700000174343586,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.013000000268220901,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/romidepsin","display_name":"romidepsin","score":0.9929999709129333},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.7289999723434448},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.6359999775886536},{"id":"https://openalex.org/keywords/drug-resistance-mechanisms","display_name":"drug resistance mechanisms","score":0.7570000290870667},{"id":"https://openalex.org/keywords/phosphoproteomics","display_name":"phosphoproteomics","score":0.7459999918937683},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8679999709129333},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7160000205039978},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5260000228881836},{"id":"https://openalex.org/keywords/oral-pi3k-inhibitor","display_name":"oral PI3K inhibitor","score":0.4259999990463257}],"concepts":[{"id":"https://openalex.org/C2781462825","wikidata":"https://www.wikidata.org/wiki/Q7363205","display_name":"Romidepsin","level":5,"score":0.967494547367096},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7617601156234741},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6650633215904236},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.49781250953674316},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.48648685216903687},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.44293272495269775},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43919339776039124},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.4319833517074585},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4195522665977478},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3238251805305481},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3148171603679657},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2540675401687622},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.2130872905254364},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.14916256070137024},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.10375997424125671},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.08932289481163025},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v130.suppl_1.819.819","doi":"https://doi.org/10.1182/blood.v130.suppl_1.819.819","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v130.suppl_1.819.819","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6800000071525574}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2908502623","https://openalex.org/W4399746551","https://openalex.org/W3174935780","https://openalex.org/W2980183364","https://openalex.org/W2952488801","https://openalex.org/W2775080684","https://openalex.org/W2784535620","https://openalex.org/W4282964230","https://openalex.org/W7172286953","https://openalex.org/W4405096196"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Current":[2],"therapies":[3],"for":[4,384,504,533,541,569,663],"relapsed/refractory":[5],"(rel/ref)":[6],"T-cell":[7,76,671],"lymphomas":[8,77,672],"(TCLs)":[9],"induce":[10],"responses":[11],"in":[12,24,33,53,60,75,78,81,85,109,132,162,177,194,204,351,370,456,517,521,526,625,670],"only":[13,461,630],"25-30%":[14],"of":[15,39,46,69,88,102,125,135,152,156,168,192,278,287,292,341,353,437,458,488,537,558,627,676,685,701,709,723,778,796,809,826,850,863,876,894,919,931,942,954],"patients":[16],"(pts).":[17],"Phosphoinositide-3-kinases":[18],"(PI3K)":[19],"play":[20],"a":[21,92,180,210,347,805],"pivotal":[22],"role":[23],"cell":[25,123,160,281],"signaling":[26],"and":[27,37,71,80,100,129,154,244,256,270,308,415,440,473,482,496,499,524,576,613,639,650,680,689,695,727],"PI3K":[28,138],"isoforms":[29],"have":[30],"distinct":[31],"roles":[32],"the":[34,47,98,118,131,166,174,304,357,362,656],"development,":[35],"function":[36],"survival":[38],"T":[40],"cells.":[41],"A":[42,142,379],"phase":[43,93,189,213],"I":[44,94,190,214],"study":[45,95,408,438,446,597],"oral":[48],"PI3K-\u03b4/\u03b3":[49],"inhibitor":[50,306],"duvelisib":[51],"(DUV)":[52],"pts":[54,110,265,368,459,508,530,539,571,628,724],"with":[55,105,111,196,338,346,673,698,718,725],"TCLs":[56],"showed":[57,284],"promising":[58],"activity":[59,134,669],"rel/ref":[61,112,205],"TCL":[62,126,175,280,348,716,729],"(Horwitz,":[63],"Blood":[64],"2014).":[65],"We":[66,116,164,185],"assessed":[67,130,165,442],"mechanisms":[68,151],"response":[70,155,172,470,477,637,643,707],"resistance":[72,153,318],"to":[73,96,149,218,311,343,361,407,445,476,492,583,596,642],"DUV":[74,103,157,169,193,224,274,300,342,667,686,690],"vitro":[79,86,133],"vivo.":[82],"Based":[83],"on":[84,170,233,240,251,261,377,502,511,543,661,774,792,822,846,859,872,890,915,927,938,950],"evidence":[87,675],"synergy,":[89],"we":[90],"initiated":[91],"evaluate":[97],"safety":[99],"efficacy":[101],"combined":[104],"romidepsin":[106,197,688],"or":[107,200,230,248,329,450,562,621,780,798,828,852,865,878,896,921,933,944,956],"bortezomib":[108,201,249,692],"TCL.":[113,206],"Methods:":[114],"Preclinical:":[115,273],"characterized":[117],"PI3K-signaling":[119],"pathway":[120],"across":[121,158,715],"11":[122,257],"lines":[124,161,282,294],"by":[127,299,303,326,330,336],"immunoblotting":[128],"isotype":[136],"specific":[137],"inhibitors,":[139],"including":[140,515,599],"DUV.":[141],"targeted":[143],"phosphoproteomic":[144,315],"approach":[145],"(P100)":[146],"was":[147,216,225,238,309,324,334,396,441],"utilized":[148],"identify":[150],"6":[159,525,538],"vitro.":[163],"effects":[167],"immune":[171],"within":[173],"microenvironment":[176],"vivo":[178],"using":[179],"patient-derived":[181],"xenograft":[182],"(PDX).":[183],"Clinical:":[184,366],"conducted":[186],"multicenter,":[187],"parallel":[188],"trials":[191],"combination":[195],"(arm":[198,202,246,258],"A)":[199,247],"B)":[203],"For":[207],"each":[208,371],"arm,":[209],"standard":[211],"3+3":[212],"design":[215],"used":[217],"determine":[219],"maximum":[220],"tolerated":[221],"dose":[222,372,389,436],"(MTD).":[223],"dosed":[226,239],"at":[227,573,579,710],"25mg,":[228],"50mg,":[229],"75mg":[231],"BID":[232],"days":[234,241,252,433,498],"1-28.":[235],"Romidepsin":[236],"10mg/m2":[237],"1,":[242,253,519],"8,":[243,255],"15":[245,529],"1mg/m2":[250],"4,":[254,467],"B),":[259],"both":[260,677,719],"28-day":[262],"cycles.":[263],"All":[264],"received":[266],"prophylaxis":[267],"against":[268],"Varicella":[269],"Pneumocystis.":[271],"Results:":[272],"potently":[275],"killed":[276],"3":[277,395,413,449,520,556,570,581,601,605,610,620],"4":[279,451,489,615,622],"that":[283],"constitutive":[285],"phosphorylation":[286],"AKT":[288],"(pAKT)":[289],"versus":[290],"0":[291],"7":[293],"lacking":[295],"pAKT":[296],"(p=0.024).":[297],"Killing":[298],"exceeded":[301],"killing":[302],"PI3K-\u03b4-specific":[305],"idelalisib":[307],"similar":[310],"pan-PI3K":[312,327],"inhibition.":[313],"The":[314,683],"analysis":[316],"identified":[317],"through":[319],"either":[320],"PI3K\u03b1":[321],"activation,":[322],"which":[323,333],"overcome":[325,335],"inhibition,":[328],"epigenetic":[331],"reprogramming,":[332],"co-treatment":[337],"romidepsin.":[339],"Administration":[340],"mice":[344],"engrafted":[345],"PDX":[349],"resulted":[350],"reprogramming":[352],"tumor-infiltrating":[354],"macrophages":[355],"from":[356,704],"immunosuppressive":[358],"M2-like":[359],"phenotype":[360],"pro-phagocytic":[363],"M1-like":[364],"phenotype.":[365],"12":[367],"(4":[369],"level":[373],"[DL])":[374],"were":[375,387,479,509,550,567,591,645,713],"treated":[376,510,572,578],"arm":[378,512],"(romidepsin+DUV);":[380],"8":[381,516,657],"are":[382,531,693,730],"evaluable":[383,532,540],"efficacy.":[385,534],"There":[386,549,590],"no":[388,551],"limiting":[390],"toxicities":[391],"(DLTs),":[392],"therefore":[393],"DL":[394,518,522,527,544,574,580,584],"accepted":[397,587],"as":[398,443,588],"MTD.":[399,589],"2":[400,417,566,575,577],"serious":[401],"adverse":[402,452],"events":[403,453],"(SAEs)":[404],"possibly":[405,594],"related":[406,595],"drug":[409,439,598],"included":[410,460,629],"grade":[411],"(Gr)":[412],"fatigue":[414],"Gr":[416,448,466,555,600,604,609,614,619],"aspartate":[418],"aminotransferase":[419,560],"(AST)":[420],"elevation.":[421],"1":[422,500,535,545,585],"fatal":[423],"event":[424],"(diffuse":[425],"alveolar":[426],"hemorrhage":[427],"following":[428,564],"allogeneic":[429],"transplant)":[430],"occurred":[431],"31":[432],"after":[434,494],"last":[435],"unrelated":[444],"treatment.":[447],"(AEs)":[454],"occurring":[455,624],"\u226510%":[457,626],"neutropenia":[462,631],"(Gr":[463,632],"3,":[464,633],"n=4,":[465],"n=2).":[468],"Overall":[469],"rate":[471],"(ORR)":[472],"median":[474,640],"time":[475,641],"(TTR)":[478],"4/8":[480],"(50%)":[481],"51":[483],"(range":[484,652],"49-54)":[485],"days.":[486,506,654,665],"Two":[487],"responders":[490],"proceeded":[491],"transplant":[493],"90":[495],"108":[497],"remains":[501],"treatment":[503,662],"107+":[505],"17":[507],"B":[513],"(bortezomib+DUV),":[514],"2,":[523],"3;":[528],"out":[536],"DLT":[542,547],"experienced":[546],"(pneumonia).":[548],"other":[552],"DLTs,":[553],"however":[554],"elevations":[557],"alanine":[559],"(ALT)":[561],"AST":[563],"cycle":[565],"observed":[568,714],"leading":[582],"being":[586],"5":[592,659],"SAEs":[593],"pneumonia":[602],"(n=2),":[603],"infectious":[606],"colitis":[607,611],"(n=1),":[608,612],"AST/ALT":[616,702],"elevation":[617,703],"(1).":[618],"AEs":[623],"n=3).":[634],"ORR,":[635],"complete":[636],"(CR),":[638],"(TTR),":[644],"8/15":[646],"(53%),":[647],"3/15":[648],"(20%),":[649],"52":[651],"47-57)":[653],"Among":[655],"responders,":[658],"remain":[660],"103-377+":[664],"Conclusion:":[666],"shows":[668],"pre-clinical":[674],"tumor":[678],"cell-autonomous":[679],"non-autonomous":[681],"effects.":[682],"combinations":[684],"plus":[687,691],"safe":[694],"well":[696],"tolerated,":[697],"limited":[699],"incidence":[700],"romidepsin+DUV.":[705],"Promising":[706],"rates":[708],"least":[711],"50%":[712],"histologies":[717],"regimens.":[720],"Expansion":[721],"cohorts":[722],"peripheral":[726],"cutaneous":[728],"currently":[731],"enrolling.":[732],"Disclosures":[733],"Moskowitz:":[734],"ADC":[735],"Therapeutics:":[736,965,990],"Research":[737,742,747,752,756,759,764,814,817,831,835,840,855,868,881,886,900,903,906,909,962,966,970,975,979,983,991,995],"Funding;":[738,743,748,757,760,815,818,832,836,841,856,869,882,887,901,904,907,910,963,967,971,976,980,984,992,996],"Seattle":[739,770,819,972],"Genetics:":[740,771,820,973],"Honoraria,":[741],"Takeda:":[744],"Honoraria;":[745],"Incyte:":[746],"Bristol":[749,761],"Myers-Squibb:":[750],"Consultancy,":[751,772,790,834,839,885,961,969,974,978,982,994],"Funding.":[753,765],"Mehta-Shah:":[754],"Celgene:":[755,787,977],"Verastem:":[758],"Myers":[762],"Squibb:":[763],"Dogan:":[766],"Roche":[767],"Pharmaceuticals:":[768],"Consultancy;":[769,786,788,986,988],"Membership":[773,791,821,845,858,871,889,914,926,937,949],"an":[775,793,823,847,860,873,891,916,928,939,951],"entity's":[776,794,824,848,861,874,892,917,929,940,952],"Board":[777,795,825,849,862,875,893,918,930,941,953],"Directors":[779,797,827,851,864,877,895,920,932,943,955],"advisory":[781,799,829,853,866,879,897,922,934,945,957],"committees;":[782,898,935,946],"Peer":[783],"Review":[784],"Institute:":[785],"Novartis:":[789],"committees.":[800,923,958],"Kim:":[801],"Millennium":[802,911],"Pharmaceuticals,":[803,912],"Inc.,":[804],"wholly":[806],"owned":[807],"subsidiary":[808],"Takeda":[810],"Pharmaceutical":[811],"Company":[812],"Limited:":[813],"Soligenix:":[816],"committees,":[830,854,867,880],"Portola:":[833],"Horizon":[837],"Pharma:":[838,884,948],"Forty":[842],"Seven":[843],"Inc:":[844],"Eisai:":[857],"Kyowa-Kirin-Pharma:":[870],"Innate":[883],"Medivir:":[888],"Merck:":[899],"miRagen:":[902],"Neumedicine:":[905],"Tetralogic:":[908],"Inc.:":[913],"Jacobsen:":[924],"GSK:":[925],"Spectrum:":[936],"Kite":[947],"Horwitz:":[959],"Forty-Seven:":[960],"Aileron":[964],"Kyowa-Hakka-Kirin:":[968],"Millenium/Takeda:":[981],"BMS:":[985],"Mundipharma:":[987],"ADCT":[989],"Infinity/Verastem:":[993],"HUYA:":[997],"Consultancy.":[998]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":4}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2019-08-13T00:00:00"}